1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Lipid Lowering Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Lipid Lowering Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Lipid Lowering Drug by Country/Region, 2018, 2022 & 2029
2.2 Lipid Lowering Drug Segment by Type
2.2.1 Statins and Combination
2.2.2 PCSK9 Inhibitors
2.2.3 Bile Acid Sequestrants
2.2.4 Fibrates
2.2.5 Cholesterol Absorption Inhibitors
2.3 Lipid Lowering Drug Sales by Type
2.3.1 Global Lipid Lowering Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Lipid Lowering Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Lipid Lowering Drug Sale Price by Type (2018-2023)
2.4 Lipid Lowering Drug Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Lipid Lowering Drug Sales by Application
2.5.1 Global Lipid Lowering Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Lipid Lowering Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Lipid Lowering Drug Sale Price by Application (2018-2023)
3 Global Lipid Lowering Drug by Company
3.1 Global Lipid Lowering Drug Breakdown Data by Company
3.1.1 Global Lipid Lowering Drug Annual Sales by Company (2018-2023)
3.1.2 Global Lipid Lowering Drug Sales Market Share by Company (2018-2023)
3.2 Global Lipid Lowering Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Lipid Lowering Drug Revenue by Company (2018-2023)
3.2.2 Global Lipid Lowering Drug Revenue Market Share by Company (2018-2023)
3.3 Global Lipid Lowering Drug Sale Price by Company
3.4 Key Manufacturers Lipid Lowering Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lipid Lowering Drug Product Location Distribution
3.4.2 Players Lipid Lowering Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Lipid Lowering Drug by Geographic Region
4.1 World Historic Lipid Lowering Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Lipid Lowering Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Lipid Lowering Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Lipid Lowering Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Lipid Lowering Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Lipid Lowering Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Lipid Lowering Drug Sales Growth
4.4 APAC Lipid Lowering Drug Sales Growth
4.5 Europe Lipid Lowering Drug Sales Growth
4.6 Middle East & Africa Lipid Lowering Drug Sales Growth
5 Americas
5.1 Americas Lipid Lowering Drug Sales by Country
5.1.1 Americas Lipid Lowering Drug Sales by Country (2018-2023)
5.1.2 Americas Lipid Lowering Drug Revenue by Country (2018-2023)
5.2 Americas Lipid Lowering Drug Sales by Type
5.3 Americas Lipid Lowering Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lipid Lowering Drug Sales by Region
6.1.1 APAC Lipid Lowering Drug Sales by Region (2018-2023)
6.1.2 APAC Lipid Lowering Drug Revenue by Region (2018-2023)
6.2 APAC Lipid Lowering Drug Sales by Type
6.3 APAC Lipid Lowering Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lipid Lowering Drug by Country
7.1.1 Europe Lipid Lowering Drug Sales by Country (2018-2023)
7.1.2 Europe Lipid Lowering Drug Revenue by Country (2018-2023)
7.2 Europe Lipid Lowering Drug Sales by Type
7.3 Europe Lipid Lowering Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lipid Lowering Drug by Country
8.1.1 Middle East & Africa Lipid Lowering Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Lipid Lowering Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Lipid Lowering Drug Sales by Type
8.3 Middle East & Africa Lipid Lowering Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lipid Lowering Drug
10.3 Manufacturing Process Analysis of Lipid Lowering Drug
10.4 Industry Chain Structure of Lipid Lowering Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lipid Lowering Drug Distributors
11.3 Lipid Lowering Drug Customer
12 World Forecast Review for Lipid Lowering Drug by Geographic Region
12.1 Global Lipid Lowering Drug Market Size Forecast by Region
12.1.1 Global Lipid Lowering Drug Forecast by Region (2024-2029)
12.1.2 Global Lipid Lowering Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Lipid Lowering Drug Forecast by Type
12.7 Global Lipid Lowering Drug Forecast by Application
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Lipid Lowering Drug Product Portfolios and Specifications
13.1.3 Sanofi Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer, Inc.
13.2.1 Pfizer, Inc. Company Information
13.2.2 Pfizer, Inc. Lipid Lowering Drug Product Portfolios and Specifications
13.2.3 Pfizer, Inc. Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer, Inc. Main Business Overview
13.2.5 Pfizer, Inc. Latest Developments
13.3 GlaxoSmithKline plc
13.3.1 GlaxoSmithKline plc Company Information
13.3.2 GlaxoSmithKline plc Lipid Lowering Drug Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline plc Main Business Overview
13.3.5 GlaxoSmithKline plc Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Lipid Lowering Drug Product Portfolios and Specifications
13.4.3 Novartis AG Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck & Co., Inc.
13.5.1 Merck & Co., Inc. Company Information
13.5.2 Merck & Co., Inc. Lipid Lowering Drug Product Portfolios and Specifications
13.5.3 Merck & Co., Inc. Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck & Co., Inc. Main Business Overview
13.5.5 Merck & Co., Inc. Latest Developments
13.6 Amgen Inc.
13.6.1 Amgen Inc. Company Information
13.6.2 Amgen Inc. Lipid Lowering Drug Product Portfolios and Specifications
13.6.3 Amgen Inc. Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc. Main Business Overview
13.6.5 Amgen Inc. Latest Developments
13.7 Takeda Pharmaceutical Company Limited
13.7.1 Takeda Pharmaceutical Company Limited Company Information
13.7.2 Takeda Pharmaceutical Company Limited Lipid Lowering Drug Product Portfolios and Specifications
13.7.3 Takeda Pharmaceutical Company Limited Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.7.5 Takeda Pharmaceutical Company Limited Latest Developments
13.8 Sun Pharmaceutical Industries Ltd.
13.8.1 Sun Pharmaceutical Industries Ltd. Company Information
13.8.2 Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Product Portfolios and Specifications
13.8.3 Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
13.8.5 Sun Pharmaceutical Industries Ltd. Latest Developments
13.9 AbbVie, Inc.
13.9.1 AbbVie, Inc. Company Information
13.9.2 AbbVie, Inc. Lipid Lowering Drug Product Portfolios and Specifications
13.9.3 AbbVie, Inc. Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AbbVie, Inc. Main Business Overview
13.9.5 AbbVie, Inc. Latest Developments
13.10 Viatris (Mylan N.V.)
13.10.1 Viatris (Mylan N.V.) Company Information
13.10.2 Viatris (Mylan N.V.) Lipid Lowering Drug Product Portfolios and Specifications
13.10.3 Viatris (Mylan N.V.) Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Viatris (Mylan N.V.) Main Business Overview
13.10.5 Viatris (Mylan N.V.) Latest Developments
13.11 AstraZeneca PLC
13.11.1 AstraZeneca PLC Company Information
13.11.2 AstraZeneca PLC Lipid Lowering Drug Product Portfolios and Specifications
13.11.3 AstraZeneca PLC Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca PLC Main Business Overview
13.11.5 AstraZeneca PLC Latest Developments
13.12 Dr. Reddy’s Laboratories Ltd.
13.12.1 Dr. Reddy’s Laboratories Ltd. Company Information
13.12.2 Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Product Portfolios and Specifications
13.12.3 Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Dr. Reddy’s Laboratories Ltd. Main Business Overview
13.12.5 Dr. Reddy’s Laboratories Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Lipid Lowering Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Lipid Lowering Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Statins and Combination
Table 4. Major Players of PCSK9 Inhibitors
Table 5. Major Players of Bile Acid Sequestrants
Table 6. Major Players of Fibrates
Table 7. Major Players of Cholesterol Absorption Inhibitors
Table 8. Global Lipid Lowering Drug Sales by Type (2018-2023) & (K Units)
Table 9. Global Lipid Lowering Drug Sales Market Share by Type (2018-2023)
Table 10. Global Lipid Lowering Drug Revenue by Type (2018-2023) & ($ million)
Table 11. Global Lipid Lowering Drug Revenue Market Share by Type (2018-2023)
Table 12. Global Lipid Lowering Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Lipid Lowering Drug Sales by Application (2018-2023) & (K Units)
Table 14. Global Lipid Lowering Drug Sales Market Share by Application (2018-2023)
Table 15. Global Lipid Lowering Drug Revenue by Application (2018-2023)
Table 16. Global Lipid Lowering Drug Revenue Market Share by Application (2018-2023)
Table 17. Global Lipid Lowering Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Lipid Lowering Drug Sales by Company (2018-2023) & (K Units)
Table 19. Global Lipid Lowering Drug Sales Market Share by Company (2018-2023)
Table 20. Global Lipid Lowering Drug Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Lipid Lowering Drug Revenue Market Share by Company (2018-2023)
Table 22. Global Lipid Lowering Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Lipid Lowering Drug Producing Area Distribution and Sales Area
Table 24. Players Lipid Lowering Drug Products Offered
Table 25. Lipid Lowering Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Lipid Lowering Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Lipid Lowering Drug Sales Market Share Geographic Region (2018-2023)
Table 30. Global Lipid Lowering Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Lipid Lowering Drug Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Lipid Lowering Drug Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Lipid Lowering Drug Sales Market Share by Country/Region (2018-2023)
Table 34. Global Lipid Lowering Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Lipid Lowering Drug Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Lipid Lowering Drug Sales by Country (2018-2023) & (K Units)
Table 37. Americas Lipid Lowering Drug Sales Market Share by Country (2018-2023)
Table 38. Americas Lipid Lowering Drug Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Lipid Lowering Drug Revenue Market Share by Country (2018-2023)
Table 40. Americas Lipid Lowering Drug Sales by Type (2018-2023) & (K Units)
Table 41. Americas Lipid Lowering Drug Sales by Application (2018-2023) & (K Units)
Table 42. APAC Lipid Lowering Drug Sales by Region (2018-2023) & (K Units)
Table 43. APAC Lipid Lowering Drug Sales Market Share by Region (2018-2023)
Table 44. APAC Lipid Lowering Drug Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Lipid Lowering Drug Revenue Market Share by Region (2018-2023)
Table 46. APAC Lipid Lowering Drug Sales by Type (2018-2023) & (K Units)
Table 47. APAC Lipid Lowering Drug Sales by Application (2018-2023) & (K Units)
Table 48. Europe Lipid Lowering Drug Sales by Country (2018-2023) & (K Units)
Table 49. Europe Lipid Lowering Drug Sales Market Share by Country (2018-2023)
Table 50. Europe Lipid Lowering Drug Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Lipid Lowering Drug Revenue Market Share by Country (2018-2023)
Table 52. Europe Lipid Lowering Drug Sales by Type (2018-2023) & (K Units)
Table 53. Europe Lipid Lowering Drug Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Lipid Lowering Drug Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Lipid Lowering Drug Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Lipid Lowering Drug Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Lipid Lowering Drug Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Lipid Lowering Drug Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Lipid Lowering Drug Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Lipid Lowering Drug
Table 61. Key Market Challenges & Risks of Lipid Lowering Drug
Table 62. Key Industry Trends of Lipid Lowering Drug
Table 63. Lipid Lowering Drug Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Lipid Lowering Drug Distributors List
Table 66. Lipid Lowering Drug Customer List
Table 67. Global Lipid Lowering Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Lipid Lowering Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Lipid Lowering Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Lipid Lowering Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Lipid Lowering Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Lipid Lowering Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Lipid Lowering Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Lipid Lowering Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Lipid Lowering Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Lipid Lowering Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Lipid Lowering Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Lipid Lowering Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Lipid Lowering Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Lipid Lowering Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Sanofi Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Sanofi Lipid Lowering Drug Product Portfolios and Specifications
Table 83. Sanofi Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Sanofi Main Business
Table 85. Sanofi Latest Developments
Table 86. Pfizer, Inc. Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Pfizer, Inc. Lipid Lowering Drug Product Portfolios and Specifications
Table 88. Pfizer, Inc. Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. Pfizer, Inc. Main Business
Table 90. Pfizer, Inc. Latest Developments
Table 91. GlaxoSmithKline plc Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. GlaxoSmithKline plc Lipid Lowering Drug Product Portfolios and Specifications
Table 93. GlaxoSmithKline plc Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. GlaxoSmithKline plc Main Business
Table 95. GlaxoSmithKline plc Latest Developments
Table 96. Novartis AG Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis AG Lipid Lowering Drug Product Portfolios and Specifications
Table 98. Novartis AG Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Novartis AG Main Business
Table 100. Novartis AG Latest Developments
Table 101. Merck & Co., Inc. Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Merck & Co., Inc. Lipid Lowering Drug Product Portfolios and Specifications
Table 103. Merck & Co., Inc. Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Merck & Co., Inc. Main Business
Table 105. Merck & Co., Inc. Latest Developments
Table 106. Amgen Inc. Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Amgen Inc. Lipid Lowering Drug Product Portfolios and Specifications
Table 108. Amgen Inc. Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Amgen Inc. Main Business
Table 110. Amgen Inc. Latest Developments
Table 111. Takeda Pharmaceutical Company Limited Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Takeda Pharmaceutical Company Limited Lipid Lowering Drug Product Portfolios and Specifications
Table 113. Takeda Pharmaceutical Company Limited Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Takeda Pharmaceutical Company Limited Main Business
Table 115. Takeda Pharmaceutical Company Limited Latest Developments
Table 116. Sun Pharmaceutical Industries Ltd. Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Product Portfolios and Specifications
Table 118. Sun Pharmaceutical Industries Ltd. Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. Sun Pharmaceutical Industries Ltd. Main Business
Table 120. Sun Pharmaceutical Industries Ltd. Latest Developments
Table 121. AbbVie, Inc. Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. AbbVie, Inc. Lipid Lowering Drug Product Portfolios and Specifications
Table 123. AbbVie, Inc. Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. AbbVie, Inc. Main Business
Table 125. AbbVie, Inc. Latest Developments
Table 126. Viatris (Mylan N.V.) Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. Viatris (Mylan N.V.) Lipid Lowering Drug Product Portfolios and Specifications
Table 128. Viatris (Mylan N.V.) Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 129. Viatris (Mylan N.V.) Main Business
Table 130. Viatris (Mylan N.V.) Latest Developments
Table 131. AstraZeneca PLC Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. AstraZeneca PLC Lipid Lowering Drug Product Portfolios and Specifications
Table 133. AstraZeneca PLC Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 134. AstraZeneca PLC Main Business
Table 135. AstraZeneca PLC Latest Developments
Table 136. Dr. Reddy’s Laboratories Ltd. Basic Information, Lipid Lowering Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Product Portfolios and Specifications
Table 138. Dr. Reddy’s Laboratories Ltd. Lipid Lowering Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 139. Dr. Reddy’s Laboratories Ltd. Main Business
Table 140. Dr. Reddy’s Laboratories Ltd. Latest Developments
List of Figures
Figure 1. Picture of Lipid Lowering Drug
Figure 2. Lipid Lowering Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Lipid Lowering Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Lipid Lowering Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Lipid Lowering Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Statins and Combination
Figure 10. Product Picture of PCSK9 Inhibitors
Figure 11. Product Picture of Bile Acid Sequestrants
Figure 12. Product Picture of Fibrates
Figure 13. Product Picture of Cholesterol Absorption Inhibitors
Figure 14. Global Lipid Lowering Drug Sales Market Share by Type in 2022
Figure 15. Global Lipid Lowering Drug Revenue Market Share by Type (2018-2023)
Figure 16. Lipid Lowering Drug Consumed in Hospital Pharmacies
Figure 17. Global Lipid Lowering Drug Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 18. Lipid Lowering Drug Consumed in Retail Pharmacies
Figure 19. Global Lipid Lowering Drug Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 20. Lipid Lowering Drug Consumed in Online Pharmacies
Figure 21. Global Lipid Lowering Drug Market: Online Pharmacies (2018-2023) & (K Units)
Figure 22. Global Lipid Lowering Drug Sales Market Share by Application (2022)
Figure 23. Global Lipid Lowering Drug Revenue Market Share by Application in 2022
Figure 24. Lipid Lowering Drug Sales Market by Company in 2022 (K Units)
Figure 25. Global Lipid Lowering Drug Sales Market Share by Company in 2022
Figure 26. Lipid Lowering Drug Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Lipid Lowering Drug Revenue Market Share by Company in 2022
Figure 28. Global Lipid Lowering Drug Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Lipid Lowering Drug Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Lipid Lowering Drug Sales 2018-2023 (K Units)
Figure 31. Americas Lipid Lowering Drug Revenue 2018-2023 ($ Millions)
Figure 32. APAC Lipid Lowering Drug Sales 2018-2023 (K Units)
Figure 33. APAC Lipid Lowering Drug Revenue 2018-2023 ($ Millions)
Figure 34. Europe Lipid Lowering Drug Sales 2018-2023 (K Units)
Figure 35. Europe Lipid Lowering Drug Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Lipid Lowering Drug Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Lipid Lowering Drug Revenue 2018-2023 ($ Millions)
Figure 38. Americas Lipid Lowering Drug Sales Market Share by Country in 2022
Figure 39. Americas Lipid Lowering Drug Revenue Market Share by Country in 2022
Figure 40. Americas Lipid Lowering Drug Sales Market Share by Type (2018-2023)
Figure 41. Americas Lipid Lowering Drug Sales Market Share by Application (2018-2023)
Figure 42. United States Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Lipid Lowering Drug Sales Market Share by Region in 2022
Figure 47. APAC Lipid Lowering Drug Revenue Market Share by Regions in 2022
Figure 48. APAC Lipid Lowering Drug Sales Market Share by Type (2018-2023)
Figure 49. APAC Lipid Lowering Drug Sales Market Share by Application (2018-2023)
Figure 50. China Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Lipid Lowering Drug Sales Market Share by Country in 2022
Figure 58. Europe Lipid Lowering Drug Revenue Market Share by Country in 2022
Figure 59. Europe Lipid Lowering Drug Sales Market Share by Type (2018-2023)
Figure 60. Europe Lipid Lowering Drug Sales Market Share by Application (2018-2023)
Figure 61. Germany Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Lipid Lowering Drug Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Lipid Lowering Drug Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Lipid Lowering Drug Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Lipid Lowering Drug Sales Market Share by Application (2018-2023)
Figure 70. Egypt Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Lipid Lowering Drug Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Lipid Lowering Drug in 2022
Figure 76. Manufacturing Process Analysis of Lipid Lowering Drug
Figure 77. Industry Chain Structure of Lipid Lowering Drug
Figure 78. Channels of Distribution
Figure 79. Global Lipid Lowering Drug Sales Market Forecast by Region (2024-2029)
Figure 80. Global Lipid Lowering Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Lipid Lowering Drug Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Lipid Lowering Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Lipid Lowering Drug Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Lipid Lowering Drug Revenue Market Share Forecast by Application (2024-2029)

※参考情報 脂質低下薬は、血液中の脂質、特にコレステロールおよびトリグリセリドのレベルを低下させることを目的とした医薬品です。これらの脂質は、心血管疾患を含むさまざまな健康問題と深く関連しています。そのため、脂質低下薬は心臓病、脳卒中、動脈硬化等の予防や治療において重要な役割を果たしています。ここでは、脂質低下薬の定義、特徴、種類、用途、および関連技術について詳述します。 脂質低下薬の定義としては、血液中の脂質成分を調整し、脂質の過剰な蓄積を防ぐことで、心血管系の健康を促進する医薬品群と理解されます。これらの薬剤は、非常に多様な作用機序を持っており、個々の患者の病状や生活習慣に合わせて処方されることが一般的です。脂質の異常は主に高コレステロール血症や高脂血症として認識され、治療においては食事療法や生活習慣の改善が基本となりますが、薬物治療が求められる場合も少なくありません。 脂質低下薬の特徴としては、まずその作用機序が挙げられます。多くの脂質低下薬は、体内での脂質の生成や吸収を抑制することで効果を発揮します。その一方で、脂質の排泄を促進する薬剤も存在します。また、患者ごとに異なる脂質異常のパターンに応じた個別化医療が進んでおり、必要に応じて複数の薬剤を併用することで治療効果を高めることが行われています。 脂質低下薬にはさまざまな種類があります。一般的に用いられる脂質低下薬の代表としては、スタチン系薬剤、フィブラート系薬剤、ニコチン酸製剤、コレステロール吸収抑制薬、PCSK9阻害薬などが挙げられます。スタチン系薬剤は、肝臓におけるコレステロールの合成を抑えることにより、LDLコレステロール（悪玉コレステロール）の低下を促進します。これにより心血管疾患のリスクが低下することが示されています。 次に、フィブラート系薬剤は主にトリグリセリドの低下に寄与します。これらは肝臓や脂肪組織での脂質代謝を調節し、IDL（中間密度リポタンパク質）やVLDL（超低密度リポタンパク質）の減少を促します。ニコチン酸製剤は、脂肪組織からの遊離脂肪酸の放出を抑えることで、肝臓でのトリグリセリドの合成を減少させる効果があります。 コレステロール吸収抑制薬は、腸内でのコレステロールの吸収を阻害することにより、血中コレステロール濃度を低下させます。この薬剤もスタチン系薬剤と併用されることが多く、相乗効果が期待されています。最後に、PCSK9阻害薬は新しいクラスの脂質低下薬であり、LDLコレステロールの代謝を改善し、LDL受容体の活性を高めることで血中のLDLコレステロールを顕著に低下させます。 脂質低下薬の用途は多岐にわたりますが、主に心血管疾患の予防と治療が挙げられます。高脂血症や動脈硬化が進行することで、冠動脈疾患や脳卒中のリスクが増加しますが、脂質低下薬を用いることでこれらの疾患の発症リスクを低減させることが可能です。また、遺伝性高コレステロール血症などの特異なケースにも対応できる薬剤があり、個別の治療において幅広い選択肢を提供しています。 最近では、技術の進展により遺伝子治療や新薬の開発が進む中、脂質低下薬の効果や副作用に関する研究も活発に行われています。特に、PCSK9阻害薬のような新しい薬剤は、従来の治療法に対して新しいアプローチを提供しており、より効果的な治療が期待されています。さらには、生活習慣の改善や食事に関する研究も進められており、これらの知見が薬物治療と結びつくことで、さらなる治療効果が見込まれています。 脂質低下薬の使用に際しては、副作用や相互作用の観点から注意が必要です。特にスタチン系薬剤は、肝機能障害や筋肉痛、横紋筋融解症などの副作用が報告されています。このため、使用前には患者の病歴を十分に把握し、必要な検査を行ってリスクを最小限に抑えることが重要です。 さらに、個々の患者に合わせた治療戦略を立てることが効果的です。患者の生活習慣や食事、運動習慣に応じて、薬剤の種類や用量を調整することで、より良い治療効果を得ることができます。また、遵守率を向上させるための指導やサポートも必要です。患者が自身の健康管理に積極的に関与できるよう、情報提供や生活指導を行うことで、長期的な治療成績を向上させることができるでしょう。 以上のように、脂質低下薬は心血管疾患の予防および治療において重要な役割を果たしており、多様な種類と新しい技術の開発が進む中で、今後の薬物治療の発展が期待されています。患者の生活の質を向上させるためにも、これらの薬剤の効果的な使用が求められています。各薬剤の特性や使用方法に関して理解を深め、適切な治療を行うことが重要です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer